Suppression of elevated alanine aminotransferase activity in liver disease by vigabatrin

J Paediatr Child Health. 1998 Aug;34(4):395-7. doi: 10.1046/j.1440-1754.1998.00249.x.

Abstract

A patient with hepatic cirrhosis due to Alpers disease is described who had a significantly raised plasma alanine aminotransferase (ALT) activity of 247 U/L which returned to normal (18 U/L) shortly after commencing treatment with the anticonvulsant drug, vigabatrin. Previous studies have reported smaller reductions in plasma ALT activity due to vigabatrin, generally in patients with normal liver function. This case demonstrates that vigabatrin may also reduce markedly elevated ALT activity to the normal range in patients with documented liver disease. Plasma ALT activity cannot be used as an index of liver cell damage in patients receiving vigabatrin.

Publication types

  • Case Reports

MeSH terms

  • Alanine Transaminase / antagonists & inhibitors*
  • Anticonvulsants / pharmacology
  • Diffuse Cerebral Sclerosis of Schilder / complications
  • Enzyme Inhibitors / pharmacology*
  • Fatal Outcome
  • Humans
  • Infant
  • Liver Cirrhosis / drug therapy*
  • Liver Cirrhosis / enzymology
  • Liver Cirrhosis / etiology
  • Liver Function Tests
  • Male
  • Seizures / drug therapy
  • Seizures / etiology
  • Vigabatrin
  • gamma-Aminobutyric Acid / analogs & derivatives*
  • gamma-Aminobutyric Acid / pharmacology

Substances

  • Anticonvulsants
  • Enzyme Inhibitors
  • gamma-Aminobutyric Acid
  • Alanine Transaminase
  • Vigabatrin